Losartan Potassium Active Pharmaceutical Ingredient (API) Market Forecast Highlights Expansion From $1.97 Billion To $2.54 Billion Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Losartan Potassium Active Pharmaceutical Ingredient (API) Market Growth Potential: How Will Market Size Change Through 2030?
The market for losartan potassium active pharmaceutical ingredient (API) has experienced robust expansion in recent years, increasing from $1.85 billion in 2025 to a projected $1.97 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.5%. This growth during the historic period has been driven by several factors, including a growing incidence of hypertension, the expiration of patents on branded medications, the expansion of generic pharmaceutical production, heightened demand for cardiovascular treatments, and the broadening of global pharmaceutical supply chains.
The losartan potassium active pharmaceutical ingredient (API) market is anticipated to experience significant expansion over the upcoming years. By 2030, it is forecasted to reach a value of $2.54 billion, progressing at a compound annual growth rate (CAGR) of 6.5%. This projected growth during the forecast period is driven by several factors, including a rising global burden of cardiovascular diseases, heightened demand from emerging economies, improvements in API manufacturing techniques, a greater emphasis on eco-friendly pharmaceutical production, and the widening application of treatments for chronic kidney disease. Key trends shaping this period encompass a growing preference for generic losartan products, wider implementation of continuous flow API manufacturing methods, an increased focus on cost-effective antihypertensive APIs, broader utilization of losartan API within combination therapies, and a stronger dedication to manufacturing practices that meet stringent regulatory standards.
Download A Free Sample Report For Comprehensive Market Insights:
Losartan Potassium Active Pharmaceutical Ingredient (API) Market Expansion Supported By Key Demand Factors
The expanding prevalence of hypertension is set to drive growth in the losartan potassium active pharmaceutical ingredient (API) market in the coming period. Hypertension, characterized by consistently elevated blood pressure, increases the risk of heart disease, stroke, and various other serious health issues. This rising occurrence of hypertension is associated with diets high in salt and processed foods, which cause fluid retention and put greater strain on the heart. By blocking angiotensin II—a substance that constricts blood vessels—losartan potassium effectively manages hypertension. This action helps relax and dilate the vessels, thereby reducing blood pressure and lessening the workload on the heart. As an example, in September 2025, the World Health Organization (WHO), a Geneva, Switzerland-based global health authority, reported that around 1.4 billion adults aged 30 to 79 had hypertension in 2024, up from approximately 1.3 billion in 2022. Consequently, the increasing incidence of hypertension is fueling expansion in the losartan potassium active pharmaceutical ingredient (API) market.
Losartan Potassium Active Pharmaceutical Ingredient (API) Market Segmentation And Category Breakdown
The losartan potassium active pharmaceutical ingredient (api) market covered in this report is segmented –
1) By Product Type: Tablet, Capsule, Other Product Types
2) By Production Method: Synthetic Route, Continuous Flow Production
3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels
4) By Application: Hypertension, Heart Failure, Chronic Kidney Diseases, Other Applications
5) By End-User: Hospitals, Clinics, Pharmaceutical Companies
Subsegments:
1) By Tablet: Immediate-Release Tablets, Extended-Release Tablets, Film-Coated Tablets, Orally Disintegrating Tablets
2) By Capsule: Hard Gelatin Capsules, Modified-Release Capsules
3) By Other Product Types: Bulk Active Pharmaceutical Ingredient (API) Powder, Granules For Suspension, Pre-Formulated Intermediates
Losartan Potassium Active Pharmaceutical Ingredient (API) Market Growth Trends Influencing Competitive Dynamics
Key players in the losartan potassium active pharmaceutical ingredient (API) market are concentrating on creating novel products and securing regulatory approvals, including losartan potassium oral suspension, to improve patient adherence and broaden treatment possibilities. This oral suspension is a liquid version of losartan potassium, designed for patients who have difficulty swallowing pills. As an example, in March 2025, Scienture Holdings Inc., a biopharmaceutical firm based in the United States, obtained approval from the Food and Drug Administration (FDA) for Arbli. Arbli is a ready-to-use liquid formulation indicated for hypertension, reducing stroke risk in hypertensive patients with left ventricular hypertrophy, and managing diabetic nephropathy in individuals with type 2 diabetes. It provides accurate dosing without the need for compounding and is supplied as a 165 mL peppermint-flavored suspension (10 mg/mL), featuring an 18-month shelf life when stored at room temperature.
Losartan Potassium Active Pharmaceutical Ingredient (API) Market Competitive Analysis Of Major Industry Participants
Major companies operating in the losartan potassium active pharmaceutical ingredient (api) market are Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Ltd, Dr. Reddy’s Laboratories, Cadila Pharmaceuticals Ltd, Lupin Ltd, Zydus Lifesciences Ltd, Alkem Laboratories Ltd, IPCA Laboratories Ltd, Alembic Pharmaceuticals Ltd, Granules India Limited, Vasudha Pharma Chem Ltd, IOL Chemicals and Pharmaceuticals Limited, Unichem Laboratories Ltd, Global Pharma Tek, Hetero Drugs Ltd, Manus Aktteva Biopharma LLP, Wellona Pharma, Atom pharma, Sinoway Industrial Co. Ltd, Cerata Pharmaceuticals LLP
Access The Complete Losartan Potassium Active Pharmaceutical Ingredient (API) Market Report:
Losartan Potassium Active Pharmaceutical Ingredient (API) Market Largest Region By Revenue And Market Share
North America was the largest region in the losartan potassium API market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the losartan potassium active pharmaceutical ingredient (api) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
